Summary

The Asia Pacific dermatological drugs market stands at the forefront of global pharmaceutical expansion, propelled by the region's unprecedented population density, rapid urbanization, and escalating burden of skin diseases. Over the past five years, this market has undergone a remarkable transformation, evolving from a predominantly generic-driven landscape to one increasingly characterized by innovative biologics, JAK inhibitors, and targeted topical therapies, driven by progressive regulatory reforms across the region. India is anticipated to emerge as the second-largest and fastest-growing market in APAC, recording an impressive CAGR of 10.70% during the forecast period, fueled by increasing diagnosis rates, a rapidly expanding pharmaceutical sector, and rising investments in dermatological care. Meanwhile, Japan is projected to remain the third-largest market, contributing an incremental growth of USD 600.77 million over the 2026–2031 period, reflecting steady demand for advanced dermatological therapies in its aging population. The World Health Organization recognizes skin diseases as the third most prevalent cause of illness globally, with nearly 5 billion incident cases of skin and subcutaneous diseases reported worldwide. China accounts for over 700 million psoriasis patients, with prevalence rates of approximately 0.47%, and nearly 60% of these cases have progressed to moderate or severe disease. India faces an equally formidable challenge, with school-based surveys reporting dermatological prevalence rates ranging from 8.7% to 35%, and nearly 30% of pediatric outpatient visits and dermatology consultations involving children. Japan's rapidly aging population drives demand for dermatological therapeutics, particularly for anti-aging products and chronic skin conditions. The National Medical Products Administration in China, the Pharmaceuticals and Medical Devices Agency in Japan, and the Therapeutic Goods Administration in Australia continue to shape the therapeutic landscape through progressive approval pathways. These regulatory advancements, coupled with rising healthcare expenditure and expanding disease awareness, continue to reshape dermatological care across the Asia Pacific region.

According to the research report, "Asia-Pacific Dermatological Drugs Market Outlook, 2031," published by Bonafide Research, the Asia-Pacific Dermatological Drugs market is anticipated to grow at 9.17% CAGR from 2026 to 2031. Australia, with a current market size of USD 1.45 billion, continues to represent a mature and significant market, driven by high healthcare spending and the widespread adoption of premium dermatology products. South Korea is also expected to witness strong market expansion, with its dermatological drugs market forecast to reach USD 701.09 million by 2031, supported by increasing consumer awareness, a well-developed healthcare system, and growing demand for innovative prescription and specialty dermatology treatments across the region. This robust growth is being driven by the rising prevalence of chronic skin disorders, increasing healthcare expenditure, growing awareness of advanced dermatological therapies, and expanding access to healthcare services across emerging economies. Almirall has strengthened its Asia Pacific presence following the NMPA's approval of sarecycline hydrochloride (Seysara) for moderate-to-severe acne vulgaris in patients aged nine and above, with the product expected to reach Chinese physicians and patients in 2026. Kangzhe Pharmaceutical secured NMPA approval for ruxolitinib phosphate cream in January 2026, China's first and only targeted therapy approved for vitiligo, indicated for patients aged 12 and above with facial involvement in non-segmental vitiligo. Biocon Biologics and Yoshindo launched ustekinumab biosimilar in Japan following PMDA approval in January 2025, providing a more affordable treatment option for psoriasis vulgaris and psoriatic arthritis. The competitive landscape features substantial barriers to entry, including the high cost of clinical development and complex regulatory pathways managed by NMPA, PMDA, TGA, and India's Central Drugs Standard Control Organization.

Market Drivers

• Regulatory Modernization: Asia Pacific regulatory authorities have dramatically accelerated dermatological drug approvals. China's NMPA has implemented priority review pathways enabling efficient approval of innovative therapies such as ruxolitinib phosphate cream for vitiligo received approval in January 2026, while sarecycline for acne vulgaris gained regulatory clearance. Japan's PMDA approved ustekinumab biosimilar in January 2025, expanding treatment access. These regulatory advancements drive market expansion across the region.
• Rising Disease Burden: The Asia Pacific region bears a substantial and growing burden of dermatological conditions. WHO recognizes skin diseases as the third most prevalent cause of illness globally. China's psoriasis prevalence at 0.47% affects over 7 million individuals. Indian school-based surveys report dermatological prevalence rates from 8.7% to 35%. This immense patient population creates sustained demand for advanced dermatological therapeutics across all therapeutic categories.

Market Challenges

• Regulatory Fragmentation: The Asia Pacific region presents a complex regulatory landscape with significant variations between authorities including NMPA, PMDA, TGA, and CDSCO. Each agency maintains distinct requirements for clinical evidence, manufacturing standards, and post-marketing surveillance. This fragmentation creates substantial barriers for pharmaceutical companies seeking pan-regional market access, prolonging time-to-market and increasing development costs across multiple jurisdictions.
• Access and Affordability Gaps: Despite regulatory progress, significant disparities in healthcare access and treatment affordability persist across the region. India faces substantial gaps in atopic dermatitis management, with dermatologists reporting delayed diagnosis, preference for alternative medicine, and inappropriate treatment. Steroid phobia, lack of awareness, and cost of therapy contribute to treatment nonadherence. These barriers limit patient access to advanced dermatological therapies across emerging Asia Pacific markets.

Market Trends

• JAK Inhibitor Expansion: Janus kinase inhibitors represent a transformative drug class gaining significant momentum across Asia Pacific dermatology. Kangzhe Pharmaceutical's ruxolitinib phosphate cream received NMPA approval for vitiligo in January 2026. India's CDSCO expert committee accepted Pfizer's Phase III clinical trial data for abrocitinib, a selective JAK1 inhibitor for moderate-to-severe atopic dermatitis. These developments reflect growing clinical acceptance of JAK inhibitors across multiple indications.
• Biosimilar Market Development: Biosimilar adoption is accelerating across the region, expanding patient access to biologic therapies. Biocon Biologics launched ustekinumab biosimilar in Japan following PMDA approval. The biosimilar offers a more affordable treatment option for psoriasis vulgaris and psoriatic arthritis. This trend is expected to intensify as patent expirations create opportunities for biosimilar entry across multiple Asia Pacific markets, improving treatment affordability and access.

Psoriasis dominates the Asia Pacific dermatological drugs market due to its substantial prevalence across the region and the high proportion of patients requiring advanced biologic therapies.

Psoriasis represents the largest indication in the Asia Pacific dermatological drugs market, driven by the immense patient population across the region. China's psoriasis prevalence of approximately 0.47% translates to over 7 million patients, with nearly 60% of cases progressing to moderate or severe disease requiring systemic therapy. Large tertiary hospitals increasingly utilize multidisciplinary care involving dermatologists, rheumatologists, and immunologists for patients with complex disease. The Asia Pacific psoriasis drugs market demonstrates robust demand for advanced therapeutics. Psoriasis affects patients across all age groups, with the peak onset between ages 20 and 40 years. Approximately 40% of patients have a family history of the condition. The chronic, systemic nature of psoriasis necessitates long-term treatment, driving sustained prescription volumes. The availability of biologic therapies and oral targeted agents has expanded treatment options for moderate-to-severe cases. Increasing awareness and earlier diagnosis across the region continue to expand the addressable patient population. The rising prevalence of autoimmune triggers such as stress and environmental factors sustains market growth.

Calcineurin inhibitors are experiencing rapid growth across Asia Pacific driven by their steroid-sparing properties and expanding approval for pediatric atopic dermatitis.

Calcineurin inhibitors have emerged as the fastest-growing drug class in the Asia Pacific dermatological drugs market, driven by their unique mechanism of action and favorable safety profile. These agents offer effective steroid-sparing alternatives for managing atopic dermatitis, addressing significant unmet needs across the region. India's dermatologists report that topical calcineurin inhibitors and moisturizers are the most commonly preferred therapies for atopic dermatitis maintenance. The class addresses steroid phobia, a significant barrier to treatment adherence reported across Asian markets. NMPA approvals for pimecrolimus cream and crisaborole ointment have expanded treatment access across China. Calcineurin inhibitors are particularly valuable for treating sensitive areas including the face and intertriginous regions. The rising prevalence of atopic dermatitis across Asia Pacific with Indian studies reporting prevalence rates from 8.7% to 35% drives sustained demand. These therapies offer favorable safety profiles for long-term use in pediatric populations. The expanding therapeutic indications for calcineurin inhibitors across multiple dermatological conditions continue to drive market growth.

Topical administration maintains market leadership across Asia Pacific due to patient preference for non-invasive therapy and the substantial burden of mild-to-moderate skin conditions.

Topical administration represents the largest route of administration in the Asia Pacific dermatological drugs market, driven by the high prevalence of mild-to-moderate skin conditions amenable to localized therapy. India's dermatologists report that topical corticosteroids and calcineurin inhibitors are the preferred first-line therapies for mild-to-moderate atopic dermatitis. Topical therapies offer targeted delivery to affected areas, minimizing systemic exposure and side effects. Patient preference for non-invasive, self-administered treatments drives topical product adoption across the region. The availability of diverse topical formulations including creams, ointments, gels, and foams provides therapeutic options for various skin types and conditions. Topical therapies are particularly valuable in regions with limited healthcare infrastructure, enabling accessible treatment. The rising prevalence of atopic dermatitis, psoriasis, and acne across Asia Pacific sustains demand for topical products. The development of novel topical formulations with enhanced penetration and reduced side effect profiles continues to expand the therapeutic arsenal.

Over-the-counter dermatological drugs are experiencing moderate growth across Asia Pacific driven by increasing self-medication trends and expanding retail pharmacy networks.

Over-the-counter dermatological drugs represent a moderately growing segment in the Asia Pacific market, driven by consumer preference for accessible, affordable self-care options. China's skin care Chinese patent medicine market exceeded 7 billion yuan in 2025, reflecting substantial OTC demand. OTC products address mild skin conditions including acne, dermatitis, and fungal infections without requiring physician consultation. The expansion of retail pharmacy networks and online platforms has improved OTC product accessibility across the region. Rising consumer awareness of skin health and preventive care drives OTC product adoption. OTC dermatologicals offer affordable treatment options for price-sensitive consumers across emerging Asia Pacific markets. The availability of established OTC brands and traditional medicine-based products in China supports moderate market growth. However, growth is constrained by the limited therapeutic scope of OTC products compared to prescription alternatives for moderate-to-severe conditions.

Online pharmacies are experiencing explosive growth across Asia Pacific driven by digital health adoption, convenience, and expanding e-commerce infrastructure.

Online pharmacies represent the fastest-growing distribution channel in the Asia Pacific dermatological drugs market, driven by the region's rapid digital transformation and consumer preference for convenient healthcare access. Retail pharmacy expansions with novel offerings, including fast delivery and online distribution, add lucrative growth opportunities across Asia Pacific markets. The COVID-19 pandemic accelerated digital health adoption across the region, normalizing online pharmacy usage. Online platforms offer competitive pricing and home delivery, addressing accessibility challenges in remote areas. The integration of telemedicine with online pharmacy services enables seamless prescription fulfillment. Rising smartphone penetration and internet connectivity across emerging Asia Pacific markets support online pharmacy growth. Consumer preference for discreet purchasing of dermatological products drives online channel adoption. Regulatory frameworks across the region are evolving to accommodate and regulate online pharmaceutical distribution.

China dominates the Asia Pacific dermatological drugs market through its massive patient population, rapid regulatory modernization, and expanding pharmaceutical innovation ecosystem.

China represents the largest national market within the Asia Pacific region, is registering a CAGR of 8.42% between 2026 and 2031, supported by its large patient population, improving healthcare infrastructure, and strong demand for innovative dermatology treatments. Psoriasis affects over 7 million Chinese patients, with prevalence rates of approximately 0.47%. The NMPA has accelerated dermatological drug approvals ruxolitinib phosphate cream for vitiligo was approved in January 2026 as China's first targeted vitiligo therapy, while sarecycline received approval for acne vulgaris. Domestic pharmaceutical companies including Hengrui Medicine have advanced innovative candidates, with ivarmacitinib ointment receiving NMPA acceptance for atopic dermatitis. The Chinese dermatological drugs market demonstrates robust growth driven by increasing healthcare expenditure and disease awareness. Favorable government policies support pharmaceutical innovation and market access. Retail pharmacy expansions with digital health integration add lucrative growth opportunities. The large number of individuals seeking affordable treatments fuels sustained market expansion across China. Traditional Chinese medicine-based products continue to capture significant market share.



Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Dermatological Drugs Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Indication
• Acne
• Psoriasis
• Atopic Dermatitis
• Rosacea
• Alopecia
• Skin Cancer
• Others

By Drug Class / Molecule Type
• Corticosteroids
• Biologics
• Retinoids
• Anti-infectives
• Calcineurin Inhibitors
• Others

By Route of Administration
• Topical
• Oral
• Injectable / Parenteral

By Drug Type
• Prescription-based Drugs
• Over-the-Counter (OTC) Drugs

By Distribution channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents

Table of Content

1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Supply chain Analysis
2.5. Policy & Regulatory Framework
2.6. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. Asia-Pacific Dermatogical Drug Market Outlook
6.1. Market Size By Value
6.2. Market Share By Country
6.3. Market Size and Forecast, By Indication
6.4. Market Size and Forecast, By Drug Class / Molecule Type
6.5. Market Size and Forecast, By Route of Administration
6.6. Market Size and Forecast, By Drug Type
6.7. Market Size and Forecast, By Distribution channel
6.8. China Dermatogical Drug Market Outlook
6.8.1. Market Size by Value
6.8.2. Market Size and Forecast By Indication
6.8.3. Market Size and Forecast By Drug Class / Molecule Type
6.8.4. Market Size and Forecast By Route of Administration
6.8.5. Market Size and Forecast By Drug Type
6.8.6. Market Size and Forecast By Distribution channel
6.9. Japan Dermatogical Drug Market Outlook
6.9.1. Market Size by Value
6.9.2. Market Size and Forecast By Indication
6.9.3. Market Size and Forecast By Drug Class / Molecule Type
6.9.4. Market Size and Forecast By Route of Administration
6.9.5. Market Size and Forecast By Drug Type
6.9.6. Market Size and Forecast By Distribution channel
6.10. India Dermatogical Drug Market Outlook
6.10.1. Market Size by Value
6.10.2. Market Size and Forecast By Indication
6.10.3. Market Size and Forecast By Drug Class / Molecule Type
6.10.4. Market Size and Forecast By Route of Administration
6.10.5. Market Size and Forecast By Drug Type
6.10.6. Market Size and Forecast By Distribution channel
6.11. Australia Dermatogical Drug Market Outlook
6.11.1. Market Size by Value
6.11.2. Market Size and Forecast By Indication
6.11.3. Market Size and Forecast By Drug Class / Molecule Type
6.11.4. Market Size and Forecast By Route of Administration
6.11.5. Market Size and Forecast By Drug Type
6.11.6. Market Size and Forecast By Distribution channel
6.12. South Korea Dermatogical Drug Market Outlook
6.12.1. Market Size by Value
6.12.2. Market Size and Forecast By Indication
6.12.3. Market Size and Forecast By Drug Class / Molecule Type
6.12.4. Market Size and Forecast By Route of Administration
6.12.5. Market Size and Forecast By Drug Type
6.12.6. Market Size and Forecast By Distribution channel
7. Competitive Landscape
7.1. Competitive Dashboard
7.2. Business Strategies Adopted by Key Players
7.3. Porter's Five Forces
7.4. Company Profile
7.4.1. Galderma S.A.
7.4.1.1. Company Snapshot
7.4.1.2. Company Overview
7.4.1.3. Financial Highlights
7.4.1.4. Geographic Insights
7.4.1.5. Business Segment & Performance
7.4.1.6. Product Portfolio
7.4.1.7. Key Executives
7.4.1.8. Strategic Moves & Developments
7.4.2. LEO Pharma A/S
7.4.3. Almirall, S.A.
7.4.4. Bausch Health Companies Inc.
7.4.5. Haleon plc
7.4.6. AbbVie Inc.
7.4.7. Sanofi S.A.
7.4.8. Pfizer Inc.
7.4.9. Johnson & Johnson
7.4.10. Novartis AG
7.4.11. Eli Lilly and Company
7.4.12. Amgen Inc.
8. Strategic Recommendations
9. Annexure
9.1. FAQ`s
9.2. Notes
10. Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Figure

Figure 1: Asia-Pacific Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 2: Asia-Pacific Dermatogical Drug Market Share By Country (2025)
Figure 3: China Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: Japan Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: India Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Australia Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: South Korea Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 8: Porter's Five Forces of Global Dermatogical Drug Market

List of Table

Table 1: Influencing Factors for Dermatogical Drug Market, 2025
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: Asia-Pacific Dermatogical Drug Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)
Table 6: Asia-Pacific Dermatogical Drug Market Size and Forecast, By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 7: Asia-Pacific Dermatogical Drug Market Size and Forecast, By Route of Administration (2020 to 2031F) (In USD Billion)
Table 8: Asia-Pacific Dermatogical Drug Market Size and Forecast, By Drug Type (2020 to 2031F) (In USD Billion)
Table 9: Asia-Pacific Dermatogical Drug Market Size and Forecast, By Distribution channel (2020 to 2031F) (In USD Billion)
Table 10: China Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 11: China Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 12: China Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 13: China Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 14: China Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 15: Japan Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 16: Japan Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 17: Japan Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 18: Japan Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 19: Japan Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 20: India Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 21: India Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 22: India Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 23: India Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 24: India Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 25: Australia Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 26: Australia Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 27: Australia Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 28: Australia Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 29: Australia Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 30: South Korea Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 31: South Korea Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 32: South Korea Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 33: South Korea Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 34: South Korea Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 35: Competitive Dashboard of top 5 players, 2025